Clindamycin Injection USP; 600 mg/4 mL (150 mg/mL). 4 mL Single-dose ADD-VANTAGE Supply Disruption — Alvogen, Inc (Moderate Risk —
Clindamycin Injection USP; 600 mg/4 mL (150 mg/mL). 4 mL Single-dose ADD-VANTAGE Supply Disruption — Alvogen, Inc (Moderate Risk — is one of 9,000 drug supply records in the DrugSupply dataset. Key details — Drug name: Clindamycin Injection USP; 600 mg/4 mL (150 mg/mL). 4 mL Single-dose ADD-VANTAGE; Manufacturer: Alvog
| Drug name | Clindamycin Injection USP; 600 mg/4 mL (150 mg/mL). 4 mL Single-dose ADD-VANTAGE |
|---|---|
| Manufacturer | Alvogen, Inc |
| Recall/Disruption reason | Lack of Assurance of Sterility |
| Risk classification | Moderate Risk — Temporary Health Consequence |
| Status | Terminated |
| Record type | Enforcement/Recall |
| Recall number | D-0940-2017 |
| Initiation date | 20170616 |
| Quantity affected | 72,575 4 mL vials |
| Dosage form | Drugs |
🔍 Search all drug supply records →
$1199/mo
Try DrugSupply →